Trial Profile

Registrational study of pelareorep + paclitaxel in HR+/HER2- metastatic breast cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Pelareorep (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Registrational; Therapeutic Use

Most Recent Events

07 Mar 2025 According to an Oncolytics Biotech media release, company expect a progression-free survival (PFS) readout approximately two years after enrollment begins.
23 Dec 2024 According to an Oncolytics Biotech media release, first patient enrollment in registration-enabling study evaluating pelareorep and paclitaxel in metastatic HR+/HER2- breast cancer expected in H2 2025
10 Oct 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com